This HTML5 document contains 77 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n4http://linked.opendata.cz/resource/drugbank/drug/DB00775/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00775/identifier/chebi/
n9http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00775/identifier/wikipedia/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00775/identifier/pharmgkb/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00775/identifier/pdb/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00775/identifier/kegg-compound/
n19http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB00775/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n18http://www.rxlist.com/cgi/generic/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00775/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/patent/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00775/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n14http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00775/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00775
rdf:type
n5:Drug
n5:description
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
n5:dosage
n15:271B5E4B-363D-11E5-9242-09173F13E4C5 n15:271B5E4C-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
2 hours
n5:indication
For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.
n5:manufacturer
n12:271B5E49-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00775 n19:DB00775
dcterms:title
Tirofiban
adms:identifier
n4:54912 n7:DB00775 n21:PA451698 n23:Tirofiban n24:60947 n25:25208-001-01 n26:AGG n27:46504678 n28:9605 n29:C07965
n5:mechanismOfAction
Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of tirofiban.
n5:packager
n12:271B5E48-363D-11E5-9242-09173F13E4C5 n12:271B5E46-363D-11E5-9242-09173F13E4C5 n12:271B5E47-363D-11E5-9242-09173F13E4C5 n12:271B5E44-363D-11E5-9242-09173F13E4C5 n12:271B5E45-363D-11E5-9242-09173F13E4C5 n12:271B5E43-363D-11E5-9242-09173F13E4C5
n5:patent
n10:6136794 n10:5658929 n10:2234364 n10:2052073
n5:routeOfElimination
It is cleared from the plasma largely by renal excretion, with about 65% of an administered dose appearing in urine and about 25% in feces, both largely as unchanged tirofiban.
n5:synonym
N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine (2S)-2-(Butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid Tirofiban Tirofibanum
n5:volumeOfDistribution
* 22 to 42 L
n8:hasAHFSCode
n9:20-12-18
n5:proteinBinding
65%
n5:synthesisReference
George Roby Thomas, Dawson James Reimer, Albert D. Friesen, "TRANSDERMAL PHARMACEUTICAL PREPARATION AND ADMINISTRATION OF TIROFIBAN." U.S. Patent US20120029447, issued February 02, 2012.
foaf:page
n14:tirofiban.html n18:tiro.htm
n5:IUPAC-Name
n6:271B5E51-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5E57-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5E56-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5E53-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5E54-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5E55-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5E67-363D-11E5-9242-09173F13E4C5 n6:271B5E4F-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5E4D-363D-11E5-9242-09173F13E4C5 n6:271B5E68-363D-11E5-9242-09173F13E4C5 n6:271B5E50-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5E4E-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n22:B01AC17
n5:H-Bond-Acceptor-Count
n6:271B5E5D-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5E5E-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5E58-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5E59-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5E5B-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5E5A-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5E5C-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
144494-65-5
n5:category
n5:clearance
* 213 - 314 mL/min [Healthy subjects] * 152 - 267 mL/min [patients with coronary artery disease]
n5:containedIn
n20:271B5E4A-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B5E63-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5E65-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5E66-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5E62-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5E61-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5E64-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5E52-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5E5F-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5E60-363D-11E5-9242-09173F13E4C5